We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Cyberonics Releases More VNS Findings Amid Controversy Over Ads
Cyberonics Releases More VNS Findings Amid Controversy Over Ads
May 26, 2006
Cyberonics’ vagus nerve stimulation (VNS) therapy for treatment-resistant depression (TRD) is again at the center of controversy as a public advocacy group asked the FDA to remove an online ad the company posted, saying it exaggerates the benefits of VNS and violates FDA advertising regulations.